1.83  -0.12 (-6.15%)		11-07 16:00
Open: 1.89 High: 1.89 Volume: 511,528		Pre. Close: 1.95 Low: 1.75 Market Cap: 124(M)

Short term
Mid term
Targets	6-month :	2.47	1-year :	2.88
Resists	First :	2.11	Second :	2.47
Pivot price	2.03
Supports	First :	1.53	Second :	1.28
MAs	MA(5) :	1.91	MA(20) :	2
	MA(100) :	1.83	MA(250) :	1.8
MACD	MACD :	-0.1	Signal :	-0.1
%K %D	K(14,3) :	15.4	D(3) :	16.9
RSI	RSI(14): 42.1
52-week	High :	4.34	Low :	1.04

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ CLYM ] has closed above bottom band by 9.4%. Bollinger Bands are 0.4% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	1.89 - 1.9	1.9 - 1.91
Low:	1.73 - 1.74	1.74 - 1.75
Close:	1.81 - 1.83	1.83 - 1.85

Climb Bio, Inc., a biotechnology company, focuses on developing therapies for autoimmune-driven inflammatory diseases. It develops budoprutug, an anti-CD19 monoclonal antibody for various autoimmune diseases, including systemic lupus erythematosus and lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wilmington, Delaware.

Fri, 07 Nov 2025
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Evotec AG (EVO), Climb Bio (CLYM) and US Physical Therapy (USPH) - The Globe and Mail

Thu, 06 Nov 2025
Climb Bio, Inc. SEC 10-Q Report - TradingView

Thu, 06 Nov 2025
Climb Bio (NASDAQ: CLYM) starts Phase 2 pMN study, cleared for CLYM116 Phase 1 trial - Stock Titan

Wed, 05 Nov 2025
Climb Bio (CLYM) to Release Quarterly Earnings on Tuesday - MarketBeat

Mon, 03 Nov 2025
Climb Bio to Present at Upcoming Investor Conferences - The Manila Times

Fri, 31 Oct 2025
William Blair Initiates Coverage of Climb Bio (CLYM) with Outperform Rating on Autoimmune Drug Potential - Yahoo Finance

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	68 (M)
Shares Float	31 (M)
Held by Insiders	0.8 (%)
Held by Institutions	81.8 (%)
Shares Short	861 (K)
Shares Short P.Month	879 (K)

EPS	-0.02
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	2.74
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-15.9 %
Return on Equity (ttm)	-23 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	-40 (M)
Levered Free Cash Flow	-23 (M)

PE Ratio	-91.51
PEG Ratio	0
Price to Book value	0.66
Price to Sales	0
Price to Cash Flow	-3.13

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.